Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism

• Published in: Radiographics Vol. 41; no. 1; pp. 120 - 143
• Main Authors: Costa, Larissa B, Queiroz, Marcelo A, Barbosa, Felipe G, Nunes, Rafael F, Zaniboni, Elaine C, Ruiz, Mariana Mazo, Jardim, Denis, Gomes Marin, Jose Flavio, Cerri, Giovanni G, Buchpiguel, Carlos A
• Format: Journal Article
• Language: English
• Published: United States 01-01-2021
• ISSN: 0271-5333; 1527-1323
• DOI: 10.1148/rg.2021200093

Cancer demands precise evaluation and accurate and timely assessment of response to treatment. Imaging must be performed early during therapy to allow adjustments to the course of treatment. For decades, cross-sectional imaging provided these answers, showing responses to the treatment through changes in tumor size. However, with the emergence of immune checkpoint inhibitors, complex immune response patterns were revealed that have quickly highlighted the limitations of this approach. Patterns of response beyond tumor size have been recognized and include cystic degeneration, necrosis, hemorrhage, and cavitation. Furthermore, new unique patterns of response have surfaced, like pseudoprogression and hyperprogression, while other patterns were shown to be deceptive, such as unconfirmed progressive disease. This evolution led to new therapeutic evaluation criteria adapted specifically for immunotherapy. Moreover, inflammatory adverse effects of the immune checkpoint blockade were identified, many of which were life threatening and requiring prompt intervention. Given complex concepts like tumor microenvironment and novel therapeutic modalities in the era of personalized medicine, increasingly sophisticated imaging techniques are required to address the intricate patterns of behavior of different neoplasms. Fluorine 18-fluorodeoxyglucose PET/CT has rapidly emerged as one such technique that spans both molecular biology and immunology. This imaging technique is potentially capable of identifying and tracking prognostic biomarkers owing to its combined use of anatomic and metabolic imaging, which enables it to characterize biologic processes in vivo. This tailored approach may provide whole-body quantification of the metabolic burden of disease, providing enhanced prediction of treatment response and improved detection of adverse events.
RSNA, 2020.